Celcuity Inc. (CELC) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors, led by its candidate gedatolisib (a PI3K/AKT/mTOR inhibitor). This report covers the quarterly period ended March 31, 2025. The company has not generated any revenue to date and remains in a pre-commercial development phase.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(36.997) million | $(21.612) million |
| Net Loss Per Share (Basic/Diluted) | $(0.86) | $(0.64) |
| Operating Expenses | $36.133 million | $22.493 million |
| Cash and Cash Equivalents | $16.478 million | $22.515 million (Dec 31, 2024) |
| Short-Term Investments | $189.213 million | $212.589 million (Dec 31, 2024) |
| Total Liquidity (Cash + Investments) | $205.691 million | $235.104 million (Dec 31, 2024) |
| Long-Term Debt (Net) | $98.527 million | $97.727 million (Dec 31, 2024) |
| Accumulated Deficit | $(308.852) million | $(271.855) million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased by 71% ($15.4 million) compared to Q1 2024, driven primarily by higher operating expenses.
- R&D Expenses: Increased by 56% ($11.6 million) to $32.2 million, attributed to increased employee/consulting costs and activities supporting ongoing clinical trials (VIKTORIA-1, VIKTORIA-2, CELC-G-201).
- G&A Expenses: Increased by 112% ($2.1 million) to $3.9 million due to expanded infrastructure and professional fees.
- Interest Expense: Rose 127% to $3.2 million, reflecting the impact of the $61.7 million Term C Loan funded in May 2024.
- Cash Position: Cash and cash equivalents decreased by $6.0 million during the quarter, while total liquidity (including investments) decreased by approximately $29.4 million from the prior year-end due to operating cash outflows.
Guidance, Outlook, and Risks
- Clinical Milestones:
- VIKTORIA-1 (Phase 3, Breast Cancer): Enrollment for the PIK3CA Wild Type (WT) cohort is complete. Topline data is expected in Q3 2025. Enrollment for the PIK3CA Mutant (MT) cohort is ongoing, with data expected in Q4 2025.
- VIKTORIA-2 (Phase 3, First-Line Breast Cancer): Site activation is underway; first patient dosing is expected in Q2 2025.
- CELC-G-201 (Phase 1b/2, Prostate Cancer): Topline data for the Phase 1b portion is expected late in Q2 2025.
- Capital Resources: Management believes current cash, investments, and available borrowings under the Innovatus Loan Agreement will fund operations through 2026. The company has $125 million remaining under its Open Market Sale Agreement.
- Debt Amendment: On May 13, 2025, the company amended its loan agreement to extend the Term D Draw Period to August 31, 2025, and adjusted liquidity covenants based on milestone achievement.
- Risks: Key risks include the uncertainty of clinical trial outcomes, potential FDA regulatory delays due to government funding or leadership changes, and the need for additional capital if milestones are not met or commercialization costs exceed expectations.
Investor Verification Checklist
- Verify the timeline for VIKTORIA-1 topline data (Q3 2025) and the potential impact on the company's transition to a commercial entity.
- Monitor the achievement of the Term D Milestone by June 1, 2025, which affects liquidity covenants and the ability to draw an additional $30 million tranche.
- Review the burn rate trajectory; operating cash used was $35.9 million in Q1 2025, requiring close monitoring of the $205.7 million liquidity runway.
- Assess the impact of the amended debt agreement on future dilution, specifically the conversion rights of the Term A Loan and warrant issuances tied to future tranches.
- Confirm the status of the VIKTORIA-2 trial initiation and the safety run-in phase scheduled for Q2 2025.